JAAD Case Reports · 2016 · 100 citations · 10 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsCheckpoint Inhibitor AntibodiesCheckpoint Inhibitor CombinationsCytotoxic T Lymphocyte Antigen 4Cytotoxic T-lymphocyte-associated Protein 4 InhibitorsImmune Checkpoint Inhibitor TherapyMetastatic Melanoma TreatmentProgrammed Death-1 BlockadeProgrammed Death-1 Inhibition
Immune checkpoint inhibitors show remarkable antitumor activity across multiple tumor types, with approval of programmed death–1 (PD-1) inhibitors for non–small cell lung cancer and melanoma. A recent clinical trial found median progression-free survival of 11.5 months for combined nivolumab plus ipilimumab therapy for metastatic melanoma compared with 6.9 months (nivolumab alone) or 2.9 months (ipilimumab alone).1 Nivolumab, a fully human IgG4 PD-1 antagonist antibody, and ipilimumab, a fully human IgG1 cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antagonist antibody, act by relieving suppression of antitumor T cells.
10
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Alfons JM van den Eertwegh, Jurjen Versluis, H. Pieter van den Berg et al. · The Lancet Oncology · 2012 · 357 citations
Medicine, Immunology, Oncology +16
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Grégoire Berthod, Romain Lazor, Igor Letovanec et al. · Journal of Clinical Oncology · 2012 · 182 citations · Full text
Medicine, Immunology, Pathology +11